Login
$ERAS
$15.11 +$0.00 (0.0%) After hours

$ERAS SEC Filings

Filed On Filing
16 Nov 2026 144
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 8-K: Results of Operations and Financial Condition
12 Nov 2026 10-Q
16 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 15, 2026, Erasca, Inc. (the Company) decided to realign its leadership responsibilities to support the development and potential commercialization of its RAS-targeting programs. Responsibilities currently overseen by the Chief...

15 Oct 2026 144
15 Sep 2026 144
24 Aug 2026 8-K: Other Events

On August 24, 2026, Erasca, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation (“FTD”) to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma.

17 Aug 2026 144
14 Aug 2026 SCHEDULE 13G/A
12 Aug 2026 Form 4: Fuchs Charles S., President, R&D

Granted 1,300,000 Stock option (right to buy)

12 Aug 2026 Form 3: Fuchs Charles S., President, R&D

No securities owned

11 Aug 2026 S-8
11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination

10 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

Effective August 10, 2026, Charles S. Fuchs, M.D., M.P.H., was appointed President, Research & Development of Erasca, Inc. (“the Company”).

21 Jul 2026 144
14 Jul 2026 8-K: Other Events

31,428,572 Shares of Common Stock, par value $0.0001 per share

14 Jul 2026 424B5

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support